



**WIPO Global Challenges Seminar:  
Urgent Innovation: Policies and  
Practices for Effective Response to  
Global Health Crises**

16 April 2019


Michelle Childs  
Global Head of Policy Advocacy

# DNDi's success is only possible through innovative partnerships

Over 160 partnerships worldwide

## CRITERIA FOR SUCCESS

- ✓ Share the same vision
- ✓ Mutual understanding
- ✓ Involvement throughout the whole process



# IP & Access: DNDi vision


## Affordable treatment and equitable access to patients in need

- Delinking the costs of R&D from the price of products
- DNDi activities not financed by IP revenues
- No partnership without overcoming IP barriers which could prevent access

## Develop drugs as public goods, when possible

- Disseminate the results of DNDi work
- Encourage open publication of research data and technology transfer
- Decisions regarding ownership of patents and licensing terms made on a case-by-case basis

# DNDI's R&D and Access strategies



- Target Product Profiles: needs, acceptability, safety, quality, **end-price**
- Stakeholder involvement and public leadership from the beginning
- **Open, collaborative, drug discovery**


- **Licensing terms that reduce bottlenecks, and allow access to knowledge and medicines**
- Multisectoral stakeholder platforms
- Clinical capacity-building in public and private sector

- Adapted regulatory approaches
- Enable access and scale-up through working with treatment providers and communities
- Updated evidence-based guidance
- Technology transfer

# Pandemic Response Box (PRB) - MMV and DNDi


- **Concept:** To provide free-to-access first-line screening compounds for use in addressing future pandemic outbreaks
  - Complimentary to the existing toolboxes from MMV (e.g. Pathogen Box, Malaria Box)
  - Collection of known antibacterials, antifungals and antivirals
  - 400 diverse compounds selected based on diversity of target pathogen and mechanism of action
  - Obligation: Screening results publicly available, publish in open access journal
  - Launched Jan 2019 >35 requests for copy of the box to date

The screenshot shows the MMV (Medicines for Malaria Venture) website. The header includes the MMV logo and the tagline "Developing antimalarials to save lives". The navigation menu includes "Research & Development", "Access", "Partnering", "Our impact", "About us", "Malaria & medicines", and "Newsroom". The main content area is titled "About the Pandemic Response Box" and features a sub-header: "400 diverse drug-like molecules active against bacteria, viruses or fungi; available free of charge". Below this, there is a paragraph explaining the context of the PRB, followed by a paragraph detailing the selection process. A small image of the PRB box is also visible.



# NTD Drug Discovery Booster



**DNDi**  
Drugs for Neglected Diseases initiative





Identify new molecule of interest with moderate antiparasitic activity



Mine proprietary collections of millions of compounds to find "similar" structures



Test compounds for anti-parasitic activity




Feedback results to improve the mining process

- Speeds up the process. Cheaper : Est USD 90,000 saving per iteration
- Four hit series approved already
- Opens doors into previously inaccessible «proprietary» chemical space
- Engages cutting edge science and scientists
- Publication of results by DNDi instead of patent filing. Royalty-free licenses granted to DNDi on pre-existing IP for use in NTDs

# A pan-genotypic HCV treatment- Wide access licence

- DNDi, Pharco and Presidio agreement to test combination of sofosbuvir + ravidasvir
- Partnership with Malaysia and Thailand to conduct Phase II/III multicentre study
- Using innovative licensing agreement or TRIPS flexibilities
- Ravidasvir licence includes all MICs



## Downstream:

8 new treatments delivered since 2007



- ✓ Easy to use
- ✓ Affordable
- ✓ Field-adapted
- ✓ Non-patented



2007 **ASAQ**

**Malaria**

>500 million patients reached



2008 **ASMQ**

**Malaria**

Used in Africa and Asia



2009 **NECT**

**Sleeping sickness**

100% of stage-2 patients



2010 **SSG&PM**

**Visceral leishmaniasis in E Africa**

Now 1st line in all countries



2011 **PAEDIATRIC**

**BENZNIDAZOLE**

Chagas disease

**Two sources developed**



2011 **NEW VL TREATMENT**

**ASIA**

Visceral leishmaniasis in Asia


**Support to disease elimination**



2016 **SUPERBOOSTER THERAPY**

Paediatric HIV

**Recommended by WHO**



2018 **FEXINIDAZOLE**

**Sleeping sickness**

Approved by European Medicines Agency, first all-oral treatment

**NEW!**





# THANK YOU

TO ALL OUR  
PARTNERS &  
DONORS

**DNDi**  
Drugs for Neglected Diseases initiative

